Edwards scraps AAA program
This article was originally published in The Gray Sheet
Executive Summary
Edwards Lifesciences' inability to find a buyer for its LifePath aortic aneurysm endovascular graft system will lead to termination of the program, the company says. The only firms with endovascular surgery sales forces capable of supporting LifePath already offer AAA grafts or are developing them, Edwards explains. The company announced its intention to exit the AAA business in December (1"The Gray Sheet" Dec. 15, 2003, p. 7). European sales will end in June. Edwards says it will complete patient follow-up for a U.S. study which closed enrollment in January...